X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with SUVEN LIFE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs SUVEN LIFE - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES SUVEN LIFE VENUS REMEDIES/
SUVEN LIFE
 
P/E (TTM) x -4.1 17.2 - View Chart
P/BV x 0.2 3.8 4.0% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 VENUS REMEDIES   SUVEN LIFE
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
SUVEN LIFE
Mar-18
VENUS REMEDIES/
SUVEN LIFE
5-Yr Chart
Click to enlarge
High Rs126251 50.2%   
Low Rs61155 39.4%   
Sales per share (Unadj.) Rs301.849.1 614.3%  
Earnings per share (Unadj.) Rs-24.99.7 -255.9%  
Cash flow per share (Unadj.) Rs2.511.4 22.3%  
Dividends per share (Unadj.) Rs01.50 0.0%  
Dividend yield (eoy) %00.7 0.0%  
Book value per share (Unadj.) Rs293.360.3 486.4%  
Shares outstanding (eoy) m12.34127.28 9.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.34.1 7.5%   
Avg P/E ratio x-3.820.9 -18.0%  
P/CF ratio (eoy) x36.717.8 206.3%  
Price / Book Value ratio x0.33.4 9.5%  
Dividend payout %015.4 0.0%   
Avg Mkt Cap Rs m1,15425,825 4.5%   
No. of employees `0000.91.1 86.3%   
Total wages/salary Rs m393613 64.2%   
Avg. sales/employee Rs Th4,026.15,832.6 69.0%   
Avg. wages/employee Rs Th425.0571.5 74.4%   
Avg. net profit/employee Rs Th-331.81,153.8 -28.8%   
INCOME DATA
Net Sales Rs m3,7246,253 59.6%  
Other income Rs m23233 9.7%   
Total revenues Rs m3,7476,485 57.8%   
Gross profit Rs m3951,982 19.9%  
Depreciation Rs m338213 158.8%   
Interest Rs m35446 765.2%   
Profit before tax Rs m-2751,955 -14.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m32718 4.4%   
Profit after tax Rs m-3071,237 -24.8%  
Gross profit margin %10.631.7 33.4%  
Effective tax rate %-11.536.7 -31.2%   
Net profit margin %-8.219.8 -41.7%  
BALANCE SHEET DATA
Current assets Rs m2,6385,622 46.9%   
Current liabilities Rs m2,3051,168 197.4%   
Net working cap to sales %8.971.2 12.6%  
Current ratio x1.14.8 23.8%  
Inventory Days Days13581 166.3%  
Debtors Days Days4636 129.0%  
Net fixed assets Rs m4,8713,325 146.5%   
Share capital Rs m123127 96.9%   
"Free" reserves Rs m3,4967,547 46.3%   
Net worth Rs m3,6197,674 47.2%   
Long term debt Rs m1,37414 9,887.8%   
Total assets Rs m7,5099,135 82.2%  
Interest coverage x0.243.2 0.5%   
Debt to equity ratio x0.40 20,966.5%  
Sales to assets ratio x0.50.7 72.5%   
Return on assets %0.614.0 4.5%  
Return on equity %-8.516.1 -52.6%  
Return on capital %1.626.0 6.1%  
Exports to sales %00-   
Imports to sales %13.90-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m517NA-   
Fx inflow Rs m05,066 0.0%   
Fx outflow Rs m5172,001 25.8%   
Net fx Rs m-5173,065 -16.9%   
CASH FLOW
From Operations Rs m514699 73.5%  
From Investments Rs m-123-6 2,018.0%  
From Financial Activity Rs m-387-577 67.1%  
Net Cashflow Rs m4116 3.6%  

Share Holding

Indian Promoters % 32.9 63.4 51.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 0.0 -  
FIIs % 0.6 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 36.5 181.9%  
Shareholders   20,121 37,287 54.0%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   ELDER PHARMA  FDC LTD.  MERCK LTD  DISHMAN PHARMA  TTK HEALTHCARE  

Compare VENUS REMEDIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Macroeconomic Cues Guide the Markets This Week(Podcast)

Global markets remained in pressure this week. Pound fell sharply as risk of chaotic Brexit rose.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

SUVEN LIFE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 14, 2018 | Updated on Aug 14, 2018

Here's an analysis of the annual report of SUVEN LIFE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFE. Also includes updates on the valuation of SUVEN LIFE.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Nov 16, 2018 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - AJANTA PHARMA COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS